Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPPORT-1: CMX-2043 in PCI
NCT00984802Phase 2Completed
- Sponsor
- Ischemix, Inc.
- Start
- Feb 2010
- Primary completion
- Mar 2011
- Modality
- Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of CMX-2043 in coronary artery disease (CAD) and reperfusion injury (IRI) (4 arms), sponsored by Ischemix, Inc. Primary endpoint: Creatine Kinase-MB at 24 hours. Started Feb 2010; status: completed.
02
Drugs
CMX-2043
03
Conditions
coronary artery disease (CAD)reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT00984802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00984802.